However, anti‐inflammatory BMDMs support breast cancer cell glycolysis by secreting TGF‐β, which downregulates succinate dehydrogenase and enhances HIF1‐α‐stabilization in breast cancer cells. Here, HIF1A is linked to breast carcinoma.